title: Single point D-substituted corticotropin-releasing factor analogues: effects on potency and physicochemical characteristics.
abstract: In an attempt to determine which conformational parameters are important for the biological activity of ovine corticotropin-releasing factor (oCRF), we have synthesized in significant amounts (50-200 mg) and characterized chemically, structurally (CD), and biologically, oCRF analogues with substitution of each amino acid by its corresponding D-isomer. Out of 37 of these analogues, three were found to be equipotent to, or twice as potent as, oCRF, 13 had potencies in the range from 10 to 60%, 17 had potencies ranging from 1 to 10%, and the four others had potencies less than 0.5%. None of the analogues antagonized oCRF-induced release of ACTH in vitro at concentrations > or = 1000 oCRF. Since antagonists to CRF action can be generated by deletion of the first 8-14 residues, a series of CRF antagonists which exhibit significantly higher in vitro and in vivo biological potency than [Met18,Lys23,Glu27,29,40,Ala32,41,-Leu33,3 6,38] h/rCRF, [alpha-helical-CRF9-41], is also described. [D-Phe12,Nle21,38,Arg36]h/rCRF, in particular, was found to be ca. 15 times more potent than alpha-helical-CRF9-41 in vitro. In the rat, however, this analogue was about as effective as alpha-helical-CRF9-41 in blocking CRF-induced decrease in mean arterial blood pressure and increase in heart rate. Its potency in blocking epinephrine release by CRF was not significantly different from that of alpha-helical-CRF9-41. In the adrenalectomized rat, [Lys36]alpha-helical-CRF(9-41) (1.7 mg/kg) blunted the effect of endogenous CRF over a 90-min period; by comparison, a similar dose of alpha-helical-CRF9-41 was effective for less than 1 h.
authors.affiliation: Clayton Foundation Laboratories for Peptide Biology, Salk Institute for Biological Studies, La Jolla, California 92037.
authors.forename: J
authors.initials: J
authors.lastname: Rivier
authors.forename: C
authors.initials: C
authors.lastname: Rivier
authors.forename: R
authors.initials: R
authors.lastname: Galyean
authors.forename: A
authors.initials: A
authors.lastname: Miranda
authors.forename: C
authors.initials: C
authors.lastname: Miller
authors.forename: A G
authors.initials: AG
authors.lastname: Craig
authors.forename: G
authors.initials: G
authors.lastname: Yamamoto
authors.forename: M
authors.initials: M
authors.lastname: Brown
authors.forename: W
authors.initials: W
authors.lastname: Vale
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000595:Amino Acid Sequence; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002942:Circular Dichroism; D003346:Corticotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D004837:Epinephrine / Q000097:blood; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D008969:Molecular Sequence Data; D009638:Norepinephrine / Q000097:blood; D010455:Peptides / Q000138:chemical synthesis / Q000494:pharmacology; D017433:Protein Structure, Secondary; D051381:Rats; D017207:Rats, Sprague-Dawley; D012756:Sheep; D013329:Structure-Activity Relationship
chemical_list: D010455:Peptides; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; D009638:Norepinephrine; D004837:Epinephrine